<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Metaraminol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00610</strong>&#160; (APRD00555)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00610/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00610/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00610.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00610.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00610.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00610.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00610.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00610">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Metaraminol</td><td>German/Spanish</td><td>INN</td></tr><tr><td>M&#233;taraminol </td><td>French</td><td>INN</td></tr><tr><td>Metaraminolum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Metaraminol Bitartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001017/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001017/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001017">DBSALT001017</a></td>
      </tr>
      <tr>
        <td>
          <strong>Metaraminol Tartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001016/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001016/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001016">DBSALT001016</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aramine</td><td>Merck</td></tr><tr><td>Metaramin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pressonex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasoconstrictor-agents">Vasoconstrictor Agents</a></li>
<li><a href="/mesh/sympathomimetics">Sympathomimetics</a></li>
<li><a href="/mesh/adrenergic-alpha-1-receptor-agonists">Adrenergic alpha-1 Receptor Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>54-49-9</td></tr><tr><th>Weight</th><td>Average: 167.205<br>Monoisotopic: 167.094628665</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>13</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>WXFIGDLSSYIKKV-RCOVLWMOSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@H](N)[C@H](O)C1=CC(O)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Phenols and Derivatives; Secondary Alcohols; 1,2-Aminoalcohols; Polyamines; Enols; Monoalkylamines</td></tr><tr><th>Substituents</th><td>phenol derivative; 1,2-aminoalcohol; secondary alcohol; polyamine; enol; amine; primary amine; primary aliphatic amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage</td></tr><tr><th>Pharmacodynamics</th><td>Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both &#945;1-adrenergic receptors but appears to have no effect on &#946;-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.</td></tr><tr><th>Mechanism of action</th><td>Metaraminol acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic &amp; diastolic). Its effect is thought to be associated with the inhibition of adenyl cyclase which leads to an inhibition of the production of cAMP. Another effect of Metaraminol is that it releases norepinephrine from its storage sites indirectly.</td></tr><tr><th>Absorption</th><td>The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Approximately 45%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=240 mg/kg (rat, oral); LD<sub>50</sub>=99 mg/kg (mouse, oral)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9922</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8926</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6112</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.721</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9907</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9961</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9152</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7922</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6311</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7459</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.899</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9538</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9724</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9255</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8264</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9205</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8102
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.837
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.6456
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7863 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9126
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9492
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Merck and co inc</li>
<li>Abraxis pharmaceutical products</li>
<li>App pharmaceuticals llc</li>
<li>Elkins sinn div ah robins co inc</li>
<li>Gd searle llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intramuscular</td><td></td></tr><tr><td>Injection, solution</td><td>Intravenous drip</td><td></td></tr><tr><td>Injection, solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Metaraminol may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00211">Midodrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Moclobemide increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00206">Reserpine</a></td><td>Increased arterial pressure</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>